Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex

References

• Manthey J, Freeman TP, Kilian C, et al. Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates, the lancet regional health – Europe. L ancet Reg Health Eur. 2021;10:100227.
   PubMedGoogle Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European drug reports 2021. Trends and developments. Accessed 2021 Aug 23. Available from: https://www.emcdda.europa.eu/publications/edr/trends-developments/2021_en.
   Google Scholar
• Schmid Y, Scholz I, Mueller L, et al. Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland. Drug Alcohol Depend. 2020;206:107726.
   PubMed Web of Science ®Google Scholar
• Dines AM, Wood DM, Galicia M, Euro-DEN Research Group, et al. Presentations to the emergency department following cannabis use-a multi-centre case series from ten European countries. J Med Toxicol. 2015;11(4):415–421.
   PubMedGoogle Scholar
• Miró Ò, Waring WS, Dargan PI, on behalf of the Euro-DEN Plus Research Group, et al. Euro-DEN plus research group. Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European emergency departments. Clin Toxicol. 2021;59(10):896–904.
   PubMed Web of Science ®Google Scholar
• Ibrahim-Achi D, Miró O, Galicia M, et al. Spanish research network on drugs in hospital emergency departments — the REDUrHE registry: general analysis and comparisons between weekend and weekday poisonings. Emergencias. 2021;33:336–344.
   Web of Science ®Google Scholar
• Zuccato E, Chiabrando C, Castiglioni S, et al. Estimating community drug abuse by wastewater analysis. Environ Health Perspect. 2008; 116(8):1027–1032.
   PubMed Web of Science ®Google Scholar
• Supervía A, Salgado E, Córdoba F, et al. Poisoning cases in Catalonia: characteristics according to age groups in the intox-28 study. Emergencias. 2021;33(2):115–120.
   PubMed Web of Science ®Google Scholar
• Galicia M. Acute adverse effects of synthetic drugs: beginning to understand the magnitude of the problem in Spain. Emergencias. 2020;32(1):7–8.
   PubMed Web of Science ®Google Scholar
• Salgado García EJ. Registry of hospital emergency department visits for drug use: exploring the tip of the iceberg. Emergencias. 2021;33(5):329–330.
   PubMed Web of Science ®Google Scholar
• Smith K. Gender differences in primary substance of abuse across age groups. The CBHSQ report: April 3, 2014. Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2014.
   Google Scholar
• Dines AM, Wood DM, Yates C, Euro-DEN Research Group, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European drug emergencies network (Euro-DEN). Clin Toxicol. 2015;53(9):893–900.
   PubMed Web of Science ®Google Scholar
• Galicia M, Dargan PI, Dines AM, Euro-DEN Plus Research Group, et al. Clinical relevance of ethanol coingestion in patients with GHB/GBL intoxication. Toxicol Lett. 2019;314:37–42.
   PubMed Web of Science ®Google Scholar
• Wolfe CE, Wood DM, Dines A, Euro-DEN Research Group, et al. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN plus data-set. Neurotoxicology. 2019;73:183–187.
   PubMed Web of Science ®Google Scholar
• Miró Ò, Dargan PI, Wood DM, Euro-DEN Plus Research Group, et al. Epidemiology, clinical features and management of patients presenting to European emergency departments with acute cocaine toxicity: comparison between powder cocaine and crack cocaine cases. Clin Toxicol. 2019;57(8):718–726.
   PubMed Web of Science ®Google Scholar
• Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol. 2019;57(8):735–742.
   PubMed Web of Science ®Google Scholar
• Vallersnes OM, Dines AM, Wood DM, Euro-DEN Research Group, et al. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293.
   PubMed Web of Science ®Google Scholar
• Power RA, Verweij KJH, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201–1204.
   PubMed Web of Science ®Google Scholar
• Stefanis NC, Delespaul P, Henquet C, et al. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99(10):1333–1341.
   PubMed Web of Science ®Google Scholar
• Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19(2):187–194.
   PubMed Web of Science ®Google Scholar
• Sexton M, Cuttler C, Mischley LK. A survey of cannabis acute effects and withdrawal symptoms: differential responses across user types and age. J Altern Complement Med. 2019;25(3):326–335.
   PubMed Web of Science ®Google Scholar
• Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis Users. Cannabis Cannabinoid Res. 2016;1(1):166–175.
   PubMedGoogle Scholar
• Sara G, Burgess P, Malhi GS, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res. 2013;147(2–3):216–222.
   PubMed Web of Science ®Google Scholar
• Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.
   PubMed Web of Science ®Google Scholar
• Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav. 2003;75(2):309–318.
   PubMed Web of Science ®Google Scholar
• Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13(1):71–87.
   PubMed Web of Science ®Google Scholar
• Noblia L, Pretel Y, Merdzanovska V, et al. Cannabinoid hyperemesis syndrome: a case report. Emergencias. 2020; 32(5):377.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 2014;136:85–91.
   PubMed Web of Science ®Google Scholar
• Watanabe AH, Navaravong L, Sirilak T, et al. A systematic review and Meta-analysis of randomized controlled trials of cardiovascular toxicity of medical cannabinoids. J Am Pharm Assoc. 2021;61(5):e1–e13.
   Google Scholar
• Penetar DM, Kouri EM, Gross MM, et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend. 2005;79(2):211–223.
   PubMed Web of Science ®Google Scholar
• Manseau MW, Rajparia A, Joseph A, et al. Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Subst Use Misuse. 2017;52(6):822–825.
   PubMed Web of Science ®Google Scholar
• Johnson S, Domino EF. Some cardiovascular effects of marihuana smoking in normal volunteers. Clin Pharmacol Ther. 1971;12(5):762–768.
   PubMed Web of Science ®Google Scholar
• Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58(4):315–348.
   PubMed Web of Science ®Google Scholar
• Niesink RJ, van Laar MW. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry. 2013;4:130.
   PubMedGoogle Scholar